Table 1 Summary of baseline demographics, clinical characteristics, and analysis subgroups
| Â | Mepolizumab (100Â mg SC) | Placebo | Total |
|---|---|---|---|
N = 468 | N = 468 | N = 936 | |
Overall population | |||
 Mean (SD) age, years | 50.4 (14.25) | 50.9 (13.55) | 50.6 (13.90) |
 Female, n (%) | 265 (57) | 283 (60) | 548 (59) |
 Mean (SD) % predicted FEV1 | 58.9 (16.74) | 60.1 (16.93) | 59.5 (16.84) |
 Mean (SD) SGRQ total score | 47.6 (18.64) | 46.5 (19.25) | 47.1 (18.94) |
 Mean (SD) ACQ-5 score | 2.25 (1.17) | 2.21 (1.18) | 2.23 (1.17) |
 Receiving maintenance OCS therapy, n (%) | 116 (25) | 111 (24) | 227 (24) |
 Exacerbations in previous year, n (%) | |||
  2 | 248 (53) | 273 (58) | 521 (56) |
  3 | 96 (21) | 94 (20) | 190 (20) |
  ≥ 4 | 124 (26) | 101 (22) | 225 (24) |
 Geometric mean (SD log) eosinophil count, cells/μL | 320 (0.965) | 340 (0.929) | 330 (0.947) |
Subgroups, n (%) | |||
 Age of asthma onset ( years) | |||
  < 18 | 132 (28) | 122 (26) | 254 (27) |
  18– < 40 | 173 (37) | 172 (37) | 345 (37) |
  ≥ 40 | 162 (35) | 174 (37) | 336 (36) |
 Lung function | |||
  ≤ 60% predicted FEV1 | 245 (52) | 244 (52) | 489 (52) |
  > 60–80% predicted FEV1 | 177 (38) | 177 (38) | 354 (38) |
  > 80% predicted FEV1 | 46 (10) | 47 (10) | 93 (10) |
 Airway reversibility | |||
  na | 457 | 460 | 917 |
  Reversibleb | 312 (68) | 299 (65) | 611 (67) |
  Non-reversiblec | 145 (32) | 161 (35) | 306 (33) |
 Allergen sensitivity | |||
  na | 454 | 457 | 911 |
  Sensitivity to ≥ 1 allergen | 215 (47) | 216 (47) | 496 (54) |
  Sensitivity to ≥ 1 seasonal allergen | 144 (32) | 146 (32) | 290 (32) |
 Asthma control | |||
  na | 465 | 462 | 927 |
  Uncontrolled asthmad | 334 (72) | 314 (68) | 648 (70) |
  Partially or fully controlled asthmae | 131 (28) | 148 (32) | 279 (30) |